Beyond HbA1c : A CGM ‐centred three‐pillar framework for glycaemic variability in pre‐diabetes and type 2 diabetes

BACKGROUND: Traditional management of type 2 diabetes mellitus (T2DM) and pre-diabetes centres on HbA1c reduction, yet this single metric fails to capture glycaemic variability (GV)-an independent driver of β-cell dysfunction, endothelial damage, oxidative stress, inflammation and cardiovascular risk, even in the pre-diabetes stage. Unlike existing reviews that focus predominantly on T2DM or HbA1c-centric approaches, this perspective articulates a unified three-pillar closed-loop framework that integrates continuous glucose monitoring (CGM) across the entire pre-diabetes-to-remission continuum. PERSPECTIVE: We synthesize evidence from prospective cohorts, mechanistic studies, randomized controlled trials and real-world data to demonstrate that GV is a modifiable therapeutic target. CGM uniquely reveals dynamic glucose patterns invisible to HbA1c, enabling precise, real-time interventions that improve time in range (TIR), reduce GV and hypoglycaemia and support the achievement of clinical remission (HbA1c <48 mmol/mol (<6.5%) without glucose-lowering medication for ≥3 months) in subsets of patients. CONCLUSIONS: CGM-centred management of glycaemic stability offers a clinically actionable paradigm shift from static, average-glucose control to dynamic, precision-guided care. The proposed three-pillar framework-tiered personalized targets, data-driven intelligent decision support and empowered patient-clinician collaboration-provides a structured roadmap grounded in current evidence. Long-term outcomes in pre-diabetes, cost-effectiveness and global accessibility remain important areas for future investigation.